



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SRT3109

Cat. No.:	HY-15462		
CAS No.:	1204707-71-0		
Molecular Formula:	C ₁₈ H ₂₃ F ₂ N ₅ O ₄ S ₂		
Molecular Weight:	475.53		
Target:	CXCR		
Pathway:	GPCR/G Protein; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (210.29 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.1029 mL	10.5146 mL	21.0292 mL
	5 mM	0.4206 mL	2.1029 mL	4.2058 mL
	10 mM	0.2103 mL	1.0515 mL	2.1029 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.75 mg/mL (5.78 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.75 mg/mL (5.78 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.75 mg/mL (5.78 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SRT3109 is an antagonist of CXCR2, with a pIC₅₀ of 8.2, and used in the research of chemokine mediated diseases.

IC₅₀ & Target

CXCR2
 8.2 (pIC₅₀)

In Vitro

SRT3109 (Example 1) is an antagonist of CXCR2, with a pIC₅₀ of 8.2, and used in the research of chemokine mediated

diseases^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Patent. US20210301011A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Premji Meghani, et al. Pyrimidyl sulfonamide derivative and its use for the treatment of chemokine mediated diseases. WO2010007427A1

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA